Navigation Links
Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
Date:11/1/2011

Total Global Brand segment net revenue of approximately $445 million-- Total Distribution segment net revenue of approximately $770 million-- Adjusted EBITDA of approximately $1.1 billion -- Non-GAAP diluted earnings per share between $4.55 and $4.65Included in this forecast is the launch of Atorvastatin scheduled for November 30, 2011. We anticipate the fourth quarter contribution of the Atorvastatin launch to result in between $0.48 and $0.53 of diluted earnings per share for Watson.

Webcast and Conference Call DetailsWatson will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time to discuss third quarter 2011 financial results, the outlook for the remainder of the year and recent corporate developments.  The dial-in number to access the call is (877) 251-7980, or from international locations, (706) 643-1573.  A taped replay of the call will be available by calling (800) 642-1687 with access pass code 12286209.  The replay may be accessed from international locations by dialing (706) 645-9291 and using the same pass code.  This replay will remain in effect until midnight Eastern Standard Time, November 22, 2011.  To access the live webcast, go to Watson's Investor Relations Web site at http://ir.watson.com.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc., is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking StatementStatements contained in this press release that refer to Watson's estimated or anticipa
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
2. Watson to Present at the 2011 Annual Credit Suisse Health Care Conference
3. Watson Confirms Daytrana(R) Patent Challenge
4. Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®
5. Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)
6. Watson Confirms EMBEDA(R) Patent Challenge
7. Watson Launches Generic FEMCON(R) Fe
8. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
9. Watson to Present at the Jefferies 2011 Global Healthcare Conference
10. Watson Confirms Amphastar Patent Lawsuit
11. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014   Acutus Medical, ... invasive real-time 3D Cardiac Chamber Imaging and Dipole Density ... / or sustain complex cardiac arrhythmias, including atrial fibrillation, ... continue developing its imaging/mapping system as well as bring ... allow Acutus Medical to complete work on the AcQMap ...
(Date:9/30/2014)... , Sept. 30, 2014 In 2011, approximately ... abused prescription pain relievers (e.g. opioids). 1 ... maintenance treatment, which entails the use of buprenorphine, buprenorphine/naloxone, ... treatments are important when developing and improving care management ... benefit manager Prime Therapeutics LLC (Prime). ...
(Date:9/30/2014)... , Sept. 30, 2014  Life Science Angels ... on supporting promising emerging biotech, medical device, genomics, ... the Top Angel Investment Group in the U.S.  ... best performer out of 370 angel groups analyzed ... network strength (connections), selection aptitude and brand recognition.  ...
Breaking Medicine Technology:Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3Life Science Angels Ranked the Top Angel Investment Group in the U.S. 2Life Science Angels Ranked the Top Angel Investment Group in the U.S. 3
... Thousands of jobs in Ohio supported by the biopharmaceutical ... such as imposing new taxes in the Medicare prescription ... From research to technical work, manufacturing to construction ... services, the biopharmaceutical sector supports a broad array of ...
... 27, 2011 Codexis, Inc. (Nasdaq: CDXS ... of a joint development agreement to develop an improved ... is Brazil,s largest sugar and ethanol producer.   ... Codexis will deploy the Codexis CodeEvolver™ directed evolution technology ...
Cached Medicine Technology:Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 3Codexis, Raizen to Develop First Generation Ethanol 2Codexis, Raizen to Develop First Generation Ethanol 3
(Date:9/30/2014)... published in the October 2014 issue of The ... cancer as easy as a simple blood test. This test, ... detect some cancers earlier than ever before, but it may ... as identify those more likely to develop cancer in the ... so helping to save peoples, lives," said Diana Anderson, a ...
(Date:9/30/2014)... Doheny HealthDay Reporter , ... are given broad-spectrum antibiotics before the age of 2 ... during childhood, new research suggests. Broad-spectrum antibiotics target ... to the study. "It is a reason to ... you are picking," said lead researcher Dr. Charles Bailey, ...
(Date:9/30/2014)... September 30, 2014 Visit Pam and ... Hill and you will find a loving couple facing ... Lateral Sclerosis. , Steve was diagnosed with ... Gehrig’s Disease – just before the couple’s second wedding ... , A new video, “Care, Support & ALS,” ...
(Date:9/30/2014)... September 30, 2014 TrailMyx.com —the ... October Flavor of the Month: raw pumpkin seeds. , ... of squash”)—are rich in protein, and valued by experts ... multiple types of vitamin E. They are prized for ... and proper bowel function. , Of course, pumpkin seeds ...
(Date:9/30/2014)... Charlotte, NC (PRWEB) September 30, 2014 ... corporations and caring individuals, National Children’s Oral ... than $150,000 in grants to non-profit clinical ... NCOHF Affiliate Network and deliver comprehensive educational, ... , Recipients include:, ...
Breaking Medicine News(10 mins):Health News:New blood test determines whether you have or are likely to get cancer 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:TrailMyx.com Features October Flavor of the Month 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3
... Davenport-Ennis, National Patient Advocate Foundation President, CEO and ... Enhance Patient CareWASHINGTON, Jan. 29 Speaking on ... in the United States, National Patient Advocate Foundation ... and Founder Nancy Davenport-Ennis was invited to testify ...
... 29 Houlihan Smith,& Company, Inc. (Houlihan) completed advisory ... Health) as announced by,Charles Botchway, Group Managing Director and ... by Houlihan Smith Managing Director Reginald,McGaugh. Terms of the ... "We have been working with Mr. McGaugh and his ...
... Meditation Center of Los Angeles will present a program featuring ... an ancient practice of physical fitness, which has been used ... youthfulness in the body. The Level 1 & 2 ... Center for the Arts in Eagle Rock.The healing Taoist practice ...
... at Washington University School of Medicine in St. Louis ... in a low-oxygen, or hypoxic, environment. , They believe ... stroke, heart attack and cancer. Sensitivity to low oxygen ... The researchers report their findings in the Jan. 30 ...
... Jan. 29 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. ... a U.S. pharmaceutical company with its principal ... announced that Laiyang Jiangbo,Pharmaceutical Co., Ltd. ("Laiyang"), ... an Assets Transfer Contract (the "Contract") with,Shandong ...
... (ERT), (Nasdaq: ERES ), a leading provider ... services to the pharmaceutical, biotechnology, medical device, and related ... Company,s President and Chief Executive Officer, is scheduled to ... at 2:00 p.m. EST on February 10, 2009 at ...
Cached Medicine News:Health News:National Patient Advocate Foundation Founder Testifies Before U.S. Senate Health Committee on Methods to Improve Healthcare Quality and Patient Outcomes 2Health News:National Patient Advocate Foundation Founder Testifies Before U.S. Senate Health Committee on Methods to Improve Healthcare Quality and Patient Outcomes 3Health News:National Patient Advocate Foundation Founder Testifies Before U.S. Senate Health Committee on Methods to Improve Healthcare Quality and Patient Outcomes 4Health News:Houlihan Smith Arranges Equity Investment Into Tri-Tech Health, LLC 2Health News:World-renowned Instructor of the Healing Practice of Qigong to Teach in Los Angeles Mar. 7 & 8 2Health News:Worm provides clues about preventing damage caused by low-oxygen during stroke, heart attack 2Health News:Worm provides clues about preventing damage caused by low-oxygen during stroke, heart attack 3Health News:Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines 2Health News:Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines 3Health News:Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines 4Health News:Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines 5Health News:eResearchTechnology, Inc. to Present at the UBS Global Healthcare Services Conference on February 10, 2009 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: